{"nctId":"NCT00433836","briefTitle":"Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure","startDateStruct":{"date":"2007-01"},"conditions":["Hypertension"],"count":300,"armGroups":[{"label":"Valsartan 80 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan"]},{"label":"Valsartan 160 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan"]},{"label":"Valsartan 320 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan"]},{"label":"Enalapril 10 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril"]},{"label":"Enalapril 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril"]},{"label":"Enalapril 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril"]}],"interventions":[{"name":"Valsartan","otherNames":[]},{"name":"Enalapril","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, ages 6-17, with a documented history of hypertension\n* Must be able to swallow a pill\n* Must be ≥ 18 kg or ≤160 kg\n* MSSBP (mean of 3 measurements) must be ≥ 95th percentile, for age, gender and height, at Visit 2 (randomization), by office blood pressure measurement\n* Patients who are eligible and able to participate in the study and whose parent(s)/guardian(s) consent in writing (written informed consent) to their doing so after the purpose and nature of the investigation has been clearly explained to them. (An assent will be required for some patients depending upon their age and local requirements regarding assents)\n\nExclusion Criteria:\n\n* Renal artery stenosis\n* Current diagnosis of heart failure (NYHA Class II-IV).\n* MSSBP ≥ 25% above the 95th percentile\n* Second or third degree heart block without a pacemaker.\n* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.\n* Clinically significant valvular heart disease.\n* Patient that demonstrates clinically significant ECG abnormalities other than those associated with left ventricular hypertrophy.\n* Previous solid organ transplantation except renal, liver or heart transplantation. Renal, liver or heart transplant must have occurred at least 6 months prior to enrollment. Patient must be on stable doses of immunosuppressive therapy for 3 months and deemed clinically stable by the investigator.\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)","description":"Mean sitting systolic blood pressure (MSSBP) change after 12 weeks of treatment measured by office blood pressure measurement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.4","spread":"1.29"},{"groupId":"OG001","value":"-14.1","spread":"1.28"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)","description":"The change from baseline in mean sitting diastolic blood pressure (MSDBP) after 12 weeks of treatment as measured by office blood pressure.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"0.94"},{"groupId":"OG001","value":"-8.5","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Decrease in MSSBP to < 95th Percentile for Age, Gender and Height","description":"The percentage of children whose MSSBP decreased to \\<95th percentile for age, gender, and height on valsartan vs. enalapril monotherapy at week 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.9","spread":null},{"groupId":"OG001","value":"70.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients","description":"The effect of valsartan and enalapril between baseline and visit 6 on 24-hour mean ambulatory systolic and diastolic blood pressure (ASBP, ADBP) in a subset of patients.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":"6.75"},{"groupId":"OG001","value":"-6.8","spread":"7.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.3","spread":"6.27"},{"groupId":"OG001","value":"-5.5","spread":"5.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":151},"commonTop":["Headache","Cough","Nasopharyngitis","Pharyngitis","Upper respiratory tract infection"]}}}